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Abstract
Background: Cellulitis is a very common condition that often recurs. The PATCH II study was designed to explore
the possibility of preventing future episodes of cellulitis, with resultant cost savings for the NHS. This was the first
trial to be undertaken by the UK Dermatology Clinical Trials Network. As such, it was the first to test a recruitment
model that involved many busy clinicians each contributing just a few patients.
Methods: A double-blind randomised controlled trial comparing prophylactic antibiotics (penicillin V) with placebo
tablets, for the prevention of repeat episodes of cellulitis of the leg. Primary outcome was time to subsequent
recurrence of cellulitis.
Results: The PATCH II study was closed to recruitment having enrolled 123 participants from a target of 400.
Whilst the recruitment period was extended by 12 months, it was not possible to continue beyond this point
without additional funds. Many factors contributed to poor recruitment: (i) changes in hospital policy and the
introduction of community-based intravenous teams resulted in fewer cellulitis patients being admitted to hospital;
ii) those who were admitted were seen by many different specialties, making it difficult for a network of
dermatology clinicians to identify suitable participants; and iii) funding for research staff was limited to a trial
manager and a trial administrator at the co-ordinating centre. With no dedicated research nurses at the recruiting
centres, it was extremely difficult to maintain momentum and interest in the study. Attempts to boost recruitment
by providing some financial support for principal investigators to employ local research staff was of limited success.
Discussion: The model of a network of busy NHS clinicians all recruiting a few patients into large clinical studies
requires further testing. It did not work very well for PATCH II, but this was probably because patients were not
routinely seen by dermatologists, and recruitment took place prior to research support being available through the
Comprehensive Clinical Research Network (CCRN). There is a balance to be struck between asking a lot of centres
to recruit just a few patients, and asking a few centres to recruit a lot of patients. Giving modest funds to principal
investigators to buy local research nurse time did not work well, probably because too little research time was
bought, and it was difficult to separate research tasks from the nurses existing clinical duties. National research
infrastructure networks such as the Comprehensive Clinical Research Network will overcome many of the problems
encountered in the PATCH II trial.
Trial Registration: The trial registration number is ISRCTN03813200.
Background
Cellulitis of the leg is a painful and potentially serious
infection of the skin and subcutaneous tissue. It is a
very common condition, which was highlighted by Patri-
cia Hewitt MP in her report to the House of Commons
on ways of reducing emergency care admissions [1].
This report found that cellulitis was amongst the top
ten reasons for admission to hospital, accounting for
over 45,000 emergency admissions per year (at a total
cost of £87 million). Cellulitis is an acute condition that
requires rapid assessment and treatment. Patients are
treated by many specialties including emergency care,
general practitioners, general medicine, surgery, tissue
viability and dermatology [2]. With so many specialties
involved, the identification of potential participants for a
clinical trial involving cellulitis patients can be difficult.
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and run through the UK Dermatology Clinical Trials Net-
work (UK DCTN). The UK DCTN has charity status, and
was established about seven years ago in order to conduct
high-quality randomised controlled trials (RCTs) that
answer questions of importance to clinicians and patients.
It is now a collaborative network of just over five-hundred
dermatologists, dermatology nurses, health services
researchers and patients throughout the UK and Southern
Ireland. The Network seeks to answer important clinical
questions that have a direct impact on day-to-day clinical
practice, and which are unlikely to be answered by com-
mercially-driven pharmaceutical research.
The structure and remit of the UK DCTN was initially
modelled on the work of the UK Childhood Cancer
Study Group. However, as a result of the recommenda-
tions published by the Department of Health in ‘Best
Research for Best Health’ [3] there has recently been a
substantial investment in clinical trial infrastructure in
the UK. Five new topic specific research networks, a pri-
mary care research network and a comprehensive clinical
research network have been established [4]. The work of
the UK DCTN is supported through the Comprehensive
Clinical Research Network, which is responsible for all
disease areas not covered by one of the topic specific
research networks. Through this infrastructure, research
nurses are now in place to assist with recruitment into
both commercial and non-commercial trials in the UK.
However, these resources were not available at the time
that we were recruiting into the PATCH study.
Methods
Recruitment Model
The PATCH II trial was designed to answer the ques-
tion; “Does low dose penicillin taken after an episode of
cellulitis of the lower leg reduce the risk of further epi-
sodes?” This was a double-blind, placebo controlled ran-
domised controlled trial comparing low-dose penicillin
V with placebo. The primary outcome for the study was
time to repeat episode of cellulitis of the leg. Ethical
approval for the study was granted by Nottingham NHS
Research Ethics Committee 2 (Ref: 06/Q2404/22) and
the study was registered on the Controlled Clinical
Trials website (ISRCTN34716921).
Results
Initial sample size calculations suggested that 400 parti-
cipants were required for the study, and recruitment
was intended to take place over a 12-month period.
However, after 24 months of recruitment, the study was
closed to new recruits with just 123 (31%) participants
enrolled. The funders were unable to support our
request for a funded extension period to reach our
planned recruitment target.
Despite being a relatively common condition, recruit-
ment for the study took place in a large number of UK
centres (25+), each of which was to recruit 1-2 partici-
pants per month. This was deemed to be the best
approach for two reasons: i) it provided the opportu-
nity for ALL members of the newly formed network to
contribute to the study, and ii) the study was funded
through a medical charity (the BUPA Foundation),
which meant that insufficient funds were available to
employ dedicated research nurses to work on the
s t u d y .T h el a c ko ff u n d st oe mploy dedicated research
nurses necessitated the involvement of many investiga-
tors. To minimise the burden on recruiting investiga-
tors, participants were followed up through telephone
interviews conducted by staff at the co-ordinating cen-
tre, and were not required to return to see the recruit-
ing investigator unless they had a repeat attack of
cellulitis.
One of the reasons for choosing this study as the first
to be conducted through the UK Dermatology Clinical
Trials Network was that at the time (2006/07), patients
were generally admitted to hospital for a period of up to
ten days, giving ample time for the identification of sui-
table participants, and for obtaining informed consent.
The policy of routinely admitting cellulitis patients was
then changed with the introduction of community-based
IV teams (that offer intravenous antibiotics at home or
in a primary care setting), and the increased use of day-
treatment units to treat cellulitis patients [5,6]. This
coincided with the start of the trial and contributed to
some of the recruitment difficulties that the team faced.
Similar issues have been reported by other investigators
where changes in NHS practice and restructuring have
impacted on their ability to recruit [7].
Discussion
Was the study design at fault?
During the development of this trial, all best practices
were followed and every effort was made to ensure that
the study was well-designed and appropriate (Table 1).
The research question continues to be an important
clinical question that has been identified as a research
gap in recent cellulitis guidelines [8], and continues to
be well supported by the clinical community.
Was our model of recruitment wrong?
The model of many clinicians all contributing just a few
patients into very simple and low impact trials alongside
normal clinical duties is a model that has shaped the
development of the UK DCTN, and is critical for deter-
mining the success of such a network. Despite the diffi-
culties recruiting into the PATCH study, it is important
that work continues to establish if this model would be
effective for less common conditions that are routinely
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fundamentally flawed.
Tasks allocated to the recruiting physicians were kept
to an absolute minimum and consisted of: i) identifying
the patients; ii) confirming the diagnosis/suitability of
the participant to be randomised into the study, iii) tak-
ing informed consent and iv) prescribing the trial drugs.
All other tasks were delegated to staff at the co-ordinat-
ing centre, including randomisation of the participants,
telephone follow-up, reporting of adverse events and
data checking. Such an approach was deliberately cho-
sen in order to make best use of clinicians’ time, and
others have reported that centralising processes such as
replacing telephone randomisation with postal randomi-
sation does not compromise recruitment success [9].
Crucially for the PATCH II study, it was the initial
identification of potential participants that was difficult
and time consuming for the clinicians. In order to iden-
tify patients for the study, investigators had to search
discharge coding, accident & emergency coding and to
visit wards and departments where cellulitis patients
were regularly treated. This process was time-consum-
ing, and was clearly a large commitment for clinicians
to fit into their already busy workload. The Strategies
for Trials Enrolment and Participation Study (STEPS)
highlighted some of the key factors that might predict
successful recruitment into a trial. Not having paid trial
co-ordinators on-site was highlighted as being one of
the most important factors [10], which proved to be a
crucial stumbling block for the PATCH II study.
Providing help for centres to identify patients
In an attempt to improve recruitment, additional UK
DCTN funds were used to buy research support time at
12 of the recruiting centres. Money was provided for
between 3 and 18 months (median 6 months), and was
used to pay overtime to existing clinic or administrative
staff. The new staff were asked to help the principal
investigators to identify suitable participants for the
trial, thus reducing the administrative burden for the
clinical team. Overall, nine research nurses, and three
administrative staff were employed for between two to
four hours per week. Whilst these additional funds pro-
vided a small increase in recruitment, this was a lot less
successful than we had hoped. Feedback from centres
suggests that this was because they were unable to ring-
fence sufficient time to work on the study, and with just
a few extra hours each week, they failed to gain a sense
of ownership of the trial. These factors were felt to be
more important than whether the additional support
was provided by a nurse or by administrative staff.
Throughout the study, a variety of techniques were
used in order to boost recruitment, with varying degrees
of success. These are summarised in Table 2. Similar
strategies have been reported by other trialists [10],
although the impact of these on trial accrual is often dif-
ficult to establish.
Conclusions
Lessons learned
We are currently recruiting to a second cellulitis study
(PATCH I) and are concentrating our efforts on work-
ing with the Comprehensive Local Research Networks
(CLRNs) to support centres with dedicated research
nurses. These research nurses will not be distracted by
other clinical duties and so should be more able to iden-
tify patients for the study. Recruitment into PATCH I is
proceeding well with 186 (72%) out of a target of 260
Table 1 Factors that may predict recruitment success[10].
Relevant factors PATCH II
Quality of Study team/multi-disciplinary team Experienced multi-disciplinary team including dermatologists, trialists, statistician and health
economist. Independent Chair of Steering Committee and independent Data Monitoring Committee.
Involvement of a Clinical Trials Unit Yes - Nottingham Clinical Trials Unit (CTU)
Trial Manager Yes - based at co-ordinating centre
Local recruitment co-ordinators No - this was a major weakness for PATCH II. Local research nurses, with dedicated time to work on
the study could have made a real difference to recruitment.
Feasibility work Twelve-month feasibility study conducted prior to starting trial.
Peer reviewed study protocol Protocol peer reviewed by UK DCTN and Nottingham CTU
Simple study design Simple parallel group study (but complicated by recruitment into a similar study that was being run
in parallel).
Service user input Focus group discussions as part of feasibility study & through discussion with the Lymphoedema
Support Network
Important research question with support of
the clinical community
Identified as a priority trial by the UK Dermatology Clinical Trials Network
Drug trial/intervention only available in study Yes. Some may have felt that prophylactic antibiotics were only available to them within the trial,
although this depended very much on local practice of the treating physician.
Appropriately funded Limited funding available due to charity as the source of funding.
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time of writing this paper. Similar success in boosting
recruitment through the Comprehensive Local Research
Network has been reported elsewhere [11]. We are also
building a sense of ownership and shared responsibility
amongst the trial staff by holding regular training ses-
sions and telephone-conferences (especially between
research nurses). These provide a forum for sharing best
practices and for learning about successful recruitment
strategies in the different centres.
With the advent of the EU Clinical Trials Directive
and improved standards for the conduct of clinical trials
in the UK, it is increasingly difficult to deliver high qual-
ity non-commercial clinical trials without substantial
funding. The majority of NIHR Health Technology
Assessment funded trials now cost between £600,000 -
£1,200,000 http://www.ncchta.org/project, and such
levels of funding are simply not available from the
majority of charitable bodies that fund dermatology
research. The PATCH II trial award was for £190,000
and the charity supporting our study was not able to
support a grant extension. A review of trials funded by
the Medical Research Council and the Health Technol-
ogy Assessment programme showed that less than a
third of a cohort of 114 trials recruited to target, and
more than a third of them were granted funded trial
extensions [10]. The role of charities in being sole fun-
ders of clinical trials has to be questioned.
The Network now has two further studies underway
in bullous pemphigoid and pyoderma gangrenosum [12],
both of which are well funded through NIHR funding
bodies [13]. These studies are multi-centre (40-50
recruiting sites) and will use the same recruitment
model as PATCH II (i.e. many recruiting centres all
contributing a small number of patients). However,
there are three significant differences between these
studies and the PATCH II study; i) both studies are
recruiting patients with conditions that are routinely
treated by dermatologists; ii) the level of funding for
these studies is over four times that which is available
through charitable sources; and iii) CLRN research
nurses will be available to support the investigators in
many of the centres. We will also follow the example of
other successful investigators with experience of running
large multi-centre trials, such as the UK Collaborative
Trial of Ovarian Cancer Screening study [14]. This
study successfully recruited more than 200,000 women
into a randomised controlled trial and recommended a
highly proactive management style; a willingness to tai-
lor solutions to individual sites; automation of processes
and web-based trial management systems; the use of
training videos; and organisation of regular training
meetings in order to facilitate group discussion amongst
co-investigators and other members of the study team.
For the future the UK DCTN will need a balanced and
varied portfolio of studies. A strategic decision has been
made to develop trials of three keys types: i) trials that
rely on many investigators each providing small num-
bers of participants with an uncommon condition (e.g.
bullous pemphigoid; ii) trials of more common condi-
tions that can be done in a small number of centres
with dedicated research support (e.g. acne and eczema);
iii) trials involving specialty groups that have a particular
interest in a disease or process (e.g. trials involving der-
matology surgeons).
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